TL;DR
Sjögren's syndrome (SS) patients are increasingly developing membranous nephropathy (MN), which has become the most common kidney pathology in this autoimmune disease. While most patients can achieve remission, those with PLA2R antibodies have a poorer prognosis, highlighting the need for targeted testing and potentially more aggressive treatment strategies.
What Problem Does This Paper Address?
Sjögren's syndrome (SS) is a chronic autoimmune disease that can affect various organs, including the kidneys. While tubulointerstitial nephritis (TIN) was historically considered the most common kidney pathology in SS, recent observations suggested a shift. This paper addresses the growing prevalence and changing spectrum of kidney involvement in SS, specifically focusing on membranous nephropathy (MN). The authors aim to clarify the current prevalence of MN in SS, identify associated autoantigens (like PLA2R), and understand the long-term prognosis of SS patients with MN, particularly in relation to PLA2R status. This is crucial because understanding these patterns can lead to better diagnosis and management of kidney complications in SS.
Methods
This retrospective study analyzed data from 290 SS patients with biopsy-proven kidney involvement diagnosed between April 2007 and February 2024 at a single research center. The researchers categorized patients based on their renal pathology, with a particular focus on those diagnosed with MN. For SS-MN patients, they performed detailed serological and immunohistochemical analyses to detect specific autoantibodies and antigens, including PLA2R, EXT1/EXT2, and THSD7A. Clinical outcomes, such as complete remission (CR), partial remission (PR), and renal endpoints (defined as a significant decline in eGFR or end-stage kidney disease), were meticulously tracked over a median follow-up period of 3.52 years. Statistical analyses, including Kaplan-Meier survival analysis and Cox regression, were employed to compare outcomes between PLA2R-positive and PLA2R-negative groups and to identify independent risk factors for renal CR.
Datasets
The study utilized data from 290 SS patients with biopsy-proven kidney involvement. A subset of 74 SS-MN patients had their serum and/or renal tissue tested for PLA2R antibodies and antigens. Further testing for EXT1/EXT2 and THSD7A antigens was conducted on a subset of PLA2R-negative SS-MN patients.
Key Insights and Ideas
- The Rise of MN in SS: The most striking finding is the dramatic increase in the frequency of MN in SS patients over time, surpassing TIN as the predominant renal pathology after 2016. This suggests a significant shift in how SS affects the kidneys.
- PLA2R as a Key Player: A substantial proportion (50%) of SS-MN patients were found to be PLA2R-positive. This challenges the notion that PLA2R is exclusively associated with idiopathic MN and highlights its role in secondary MN, particularly in the context of SS.
- Beyond PLA2R: The study also identified other potential autoantigens (EXT1/EXT2 and THSD7A) in PLA2R-negative SS-MN patients, suggesting a more complex immunological landscape in this condition than previously understood.
- Prognostic Implications of PLA2R: PLA2R positivity is linked to a poorer prognosis, characterized by a longer time to achieve renal remission and a higher risk of progressing to a renal endpoint. This underscores the importance of identifying PLA2R status for risk stratification.
- Need for Targeted Testing: The findings strongly support the recommendation for PLA2R testing in SS-MN patients, followed by EXT1/EXT2 and THSD7A testing if PLA2R is negative, to better characterize the disease and guide management.
Key Results
- The frequency of MN in SS patients increased from 16.28% (2007-2010) to 44.05% (2021-2024).
- After 2016, MN became the most common renal pathologic type in SS, surpassing TIN.
- Of the 74 SS-MN patients studied, 50% were PLA2R-positive.
- Among PLA2R-negative patients, 5 out of 15 showed positivity for EXT1/EXT2 antigen, and 1 out of 8 for THSD7A antigen.
- Overall, 72.13% of SS-MN patients achieved renal complete remission (CR).
- PLA2R-positive patients took significantly longer to achieve CR (1.46 ± 1.16 years) compared to PLA2R-negative patients (0.74 ± 0.47 years, P = .015).
- PLA2R-positive patients had a higher rate of progression to the renal endpoint (25.00%) compared to PLA2R-negative patients (3.45%, P = .028).
- PLA2R positivity was identified as an independent risk factor for poorer renal CR (HR = 0.511, 95% CI (0.262 to 0.998), P = .049) even after adjusting for age, proteinuria, and eGFR.
Limitations and Future Work
The authors acknowledge that this is a retrospective study conducted at a single center, which may limit the generalizability of the findings to larger and more diverse populations. Furthermore, EXT1/EXT2 and THSD7A testing was only performed on a subset of PLA2R-negative patients, meaning the true prevalence of these antigens in this group requires further investigation. Future research could focus on prospective studies to confirm these findings, explore the role of other potential autoantigens in SS-MN, and investigate the efficacy of more aggressive or targeted therapeutic strategies, particularly for PLA2R-positive patients who may not achieve remission with standard treatments. The potential benefit of B cell-targeted therapies is also an avenue for future exploration.
Summary updated